![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--400x250.png)
Neurology Articles
A scientific hub to keep you informed about our latest research and company updates.
Home-Cage Behavior Discriminates Neurodegeneration Models from Healthy Aging Mice
Early Phenotypic Characterization of TDP-43 Q331K Mouse Model of ALS Reveals Elevated Plasma Neurofilament Light, Nerve Conduction Abnormalities and Behavioral Deficits
![Characterizing Sex Differences in the Tau[P301S] Mouse Model of Tauopathies](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/CHARACTERIZING-SEX-DIFFERENCES-IN-THE-TAUP301S-MOUSE-MODEL-OF-TAUOPATHIES--400x250.png)
Characterizing Sex Differences in the Tau[P301S] Mouse Model of Tauopathies
Characterisation of In Vitro Neuronal and Microglial Disease Models to Support Drug Discovery Efforts for Neurodegenerative Diseases
HTT1a and HTTexon1 Huntington’s disease – A new therapeutic target explored in the zQ175 mouse model
Modelling TDP-43 proteinopathy and motor neuron disease pathophysiology in mouse models
InnoSer and Carthera Launch Preclinical Access to the SonoCloud® Ultrasound Platform for CNS Drug Delivery
Neurofilament light chain (NfL) in plasma and CSF: A translational biomarker for neurodegeneration in InnoSer’s neurology mouse models
New insights into TDP-43 mouse model pathophysiology
InnoSer and CureSHANK partner to launch industry-quality preclinical testing service for Phelan-McDermid syndrome (PMS) treatments
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
info@innoserlaboratories.com